NASDAQ:BLCMBellicum Pharmaceuticals Stock Price, Forecast & News

$4.87

-0.08 (-1.62 %)

(As of 04/8/2020 01:34 PM ET)

Add

Compare

Today's Range

$4.79

Now: $4.87▼

$5.14

50-Day Range

$3.52

MA: $6.48▼

$10.42

52-Week Range

$3.32

Now: $4.87▼

$40.50

Volume48,420 shs

Average Volume162,845 shs

Market Capitalization$24.58 million

P/E RatioN/A

Dividend YieldN/A

Beta2.19

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Bellicum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Bellicum Pharmaceuticals has a potential upside of 259.3% from its current price of $4.87.
Amount of Analyst Coverage
Bellicum Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Bellicum Pharmaceuticals has received 350 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bellicum Pharmaceuticals has received 286 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bellicum Pharmaceuticals has received 55.03% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote “Outperform” if you believe BLCM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bellicum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Bellicum Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bellicum Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.64% of the stock of Bellicum Pharmaceuticals is held by insiders.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Bellicum Pharmaceuticals are expected to grow by 42.19% in the coming year, from ($12.99) to ($18.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bellicum Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bellicum Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.64 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BLCM

Previous Symbol

CUSIPN/A

CIK1358403

Webhttp://www.bellicum.com/

Phone832-384-1100

Debt

Debt-to-Equity Ratio28.20

Current Ratio1.18

Quick Ratio1.18

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.14 million

Price / Sales3.44

Cash FlowN/A

Price / Cash FlowN/A

Book Value($5.25) per share

Price / Book-0.93

Profitability

EPS (Most Recent Fiscal Year)($19.91)

Net Income$-112,480,000.00

Net Margins-1,574.65%

Return on Equity-664.19%

Return on Assets-83.28%

Miscellaneous

Employees173

Outstanding Shares5,048,000

Market Cap$24.58 million

Next Earnings Date5/5/2020 (Estimated)

OptionableOptionable

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.

Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

How has Bellicum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Bellicum Pharmaceuticals' stock was trading at $7.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BLCM stock has decreased by 33.2% and is now trading at $4.87. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellicum Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellicum Pharmaceuticals.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Bellicum Pharmaceuticals.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced its quarterly earnings data on Thursday, March, 12th. The biopharmaceutical company reported ($5.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($4.00) by $1.82. The biopharmaceutical company had revenue of $5.13 million for the quarter, compared to the consensus estimate of $0.30 million. Bellicum Pharmaceuticals had a negative net margin of 1,574.65% and a negative return on equity of 664.19%. View Bellicum Pharmaceuticals' earnings history.

When did Bellicum Pharmaceuticals' stock split? How did Bellicum Pharmaceuticals' stock split work?

Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of Bellicum Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BLCM?

1 Wall Street analysts have issued 1-year target prices for Bellicum Pharmaceuticals' shares. Their forecasts range from $17.00 to $18.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $17.50 in the next twelve months. This suggests a possible upside of 259.3% from the stock's current price. View analysts' price targets for Bellicum Pharmaceuticals.

Has Bellicum Pharmaceuticals been receiving favorable news coverage?

Media coverage about BLCM stock has been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutBellicum Pharmaceuticals.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 599,400 shares, an increase of 27.2% from the February 13th total of 471,100 shares. Based on an average daily trading volume, of 160,400 shares, the short-interest ratio is presently 3.7 days. Approximately 12.1% of the company's shares are sold short. View Bellicum Pharmaceuticals' Current Options Chain.

Who are some of Bellicum Pharmaceuticals' key competitors?

Some companies that are related to Bellicum Pharmaceuticals include GlycoMimetics (GLYC), Axovant Gene Therapies (AXGT), Aptinyx (APTX), Sierra Oncology (SRRA), PhaseBio Pharmaceuticals (PHAS), CannTrust (CTST), Five Prime Therapeutics (FPRX), Millendo Therapeutics (MLND), IDEAYA Biosciences (IDYA), Chimerix (CMRX), TFF Pharmaceuticals (TFFP), Aptorum Group (APM), SCYNEXIS (SCYX), TapImmune (MRKR) and ContraFect (CFRX).

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX) and ACADIA Pharmaceuticals (ACAD).

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the following people:

Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
Mr. Thomas J. Farrell, Consultant (Age 56)
Mr. Atabak Mokari, Chief Financial Officer (Age 42)
Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $4.87.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $24.58 million and generates $7.14 million in revenue each year. The biopharmaceutical company earns $-112,480,000.00 in net income (profit) each year or ($19.91) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe. View additional information about Bellicum Pharmaceuticals.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

NASDAQ:BLCMBellicum Pharmaceuticals Stock Price, Forecast & News

Adding

Adding

Adding Bellicum Pharmaceuticals Inc

Beat the Market (BTM) Rank™